Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Akero Therapeutics (AKRO) Misses Q2 EPS by 185c
August 12, 2019 7:14 AM EDTAkero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($2.21), $1.85 worse than the analyst estimate of ($0.36).
Second Quarter 2019 Financial Results
Research and development expenses for the three-month and six-month periods ended June 30, 2019 were $6.0 million and $10.0 million, respectively, compared to $8.4 million and $8.6 million for the comparable periods in 2018. Research and development expenses in 2019 are attributable to direct costs related to our AKR-001 program, including third-party contract manufacturing, CRO costs associated with the BALANCED trial and internal personnel costs. Research and development expenses in 2018 were primarily attributable to $8.0 million of one-time cash and non-cash product licensing... More